APSA-02 is under clinical development by Armata Pharmaceuticals and currently in Phase II for Bacteremia. According to GlobalData, Phase II drugs for Bacteremia have a 66% phase transition success ...
Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses.